Why STAAR Surgical (STAA) Is Getting Fresh Attention Now
Why STAAR Surgical’s Latest Earnings Are Getting Fresh Attention
STAAR Surgical (STAA) has returned to profitability in its latest report, which is a key reason the stock is back in focus for many investors this week.
See our latest analysis for STAAR Surgical.
STAAR Surgical’s latest earnings and leadership changes have arrived alongside a mixed price picture, with a 7.67% year to date share price return contrasting with a 5 year total shareholder return that is down 82.32%. This suggests recent momentum is improving from a weaker long term track record as investors reassess growth prospects and risk after the company’s return to profit and new CEO appointment.
If this kind of rebound has your attention, it could be a good moment to see how other healthcare focused AI stories are trading by checking out 43 healthcare AI stocks
After STAAR Surgical’s sharp swing back into profit and a modest share price recovery, the real tension now sits in the valuation. Has most of the upside already been priced in, or is there still meaningful headroom left?
Most Popular Narrative: 14.3% Undervalued
The most followed valuation narrative currently points to a fair value of $29.67 for STAAR Surgical versus a last close of $25.41, which sets up an interesting gap between modeled expectations and where the stock trades today.
STAAR Surgical has significant cash reserves and no debt, providing a strong financial base to manage the current challenges, reduce production outputs temporarily, and invest selectively in growth initiatives, potentially stabilizing earnings and providing upside if conditions improve.
Want to know what kind of revenue growth, margin rebuild, and earnings power need to come together to support that fair value gap? The full narrative spells out the path, the timing, and the profitability targets that underpin the $29.67 figure in a level of detail the headline alone cannot show.
Result: Fair Value of $29.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, STAAR Surgical’s story still carries clear risks, especially around ongoing macro weakness and distributor dependence in China that could unsettle revenue visibility and margin rebuilding.
Find out about the key risks to this STAAR Surgical narrative.
Another View On STAAR Surgical’s Valuation
The earlier narrative points to STAAR Surgical trading at a 16.5% discount to an estimated fair value of $30.44 based on future cash flows, using the SWS DCF model. That suggests the stock is undervalued today if those long term assumptions hold up.
However, on a simple P/S multiple, STAAR Surgical looks expensive. The current P/S of 4.4x sits above the US Medical Equipment industry at 2.9x, the peer average at 3.6x, and even the fair ratio estimate of 3.4x that the market could move towards. The gap points to valuation risk if growth or margins fall short of expectations.
With one method flagging upside and another indicating a premium, the key question is which signal fits better with your own valuation checklist.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of cautious optimism around STAAR Surgical has you interested, now is a good time to review the numbers yourself and stress test the upside drivers being discussed. To see the positives that stand out in the data, take a closer look at 2 key rewards.
Looking For More Investment Ideas Beyond STAAR Surgical?
If STAAR Surgical has sharpened your focus, do not stop here. Broader opportunities often emerge when you compare it with other stocks that fit clear, disciplined criteria.
- Spot potential turnaround opportunities early by checking out 19 elite penny stocks with strong financials.
- Target quality at a reasonable price by reviewing the companies in 49 high quality undervalued stocks.
- Prioritise resilience and capital strength by scanning the solid balance sheet and fundamentals stocks screener (49 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com